|
Name |
2-[[2-[(3-Pyridinylcarbonyl)amino]benzoyl]amino]-3,4,5-trimethoxybenzoic acid methyl ester
|
Molecular Formula | C24H23N3O7 | |
IUPAC Name* |
methyl 3,4,5-trimethoxy-2-[[2-(pyridine-3-carbonylamino)benzoyl]amino]benzoate
|
|
SMILES |
COC1=C(C(=C(C(=C1)C(=O)OC)NC(=O)C2=CC=CC=C2NC(=O)C3=CN=CC=C3)OC)OC
|
|
InChI |
InChI=1S/C24H23N3O7/c1-31-18-12-16(24(30)34-4)19(21(33-3)20(18)32-2)27-23(29)15-9-5-6-10-17(15)26-22(28)14-8-7-11-25-13-14/h5-13H,1-4H3,(H,26,28)(H,27,29)
|
|
InChIKey |
DXZREYMSIRCHNS-UHFFFAOYSA-N
|
|
Synonyms |
81469-77-4; 2-[[2-[(3-Pyridinylcarbonyl)amino]benzoyl]amino]-3,4,5-trimethoxybenzoic acid methyl ester; methyl 3,4,5-trimethoxy-2-[[2-(pyridine-3-carbonylamino)benzoyl]amino]benzoate; Methyl 3,4,5-trimethoxy-2-(2-(nicotinamido)benzamido)benzoate; 3,4,5-trimethoxy-2-[[2-[(3-pyridinylcarbonyl)amino]benzoyl]amino]-benzoic acid, methyl ester; Preterremide C; HY-N10261; CS-0371834
|
|
CAS | NA | |
PubChem CID | 12961683 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 465.5 | ALogp: | 3.4 |
HBD: | 2 | HBA: | 8 |
Rotatable Bonds: | 9 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 125.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 34 | QED Weighted: | 0.476 |
Caco-2 Permeability: | -4.798 | MDCK Permeability: | 0.00001730 |
Pgp-inhibitor: | 0.981 | Pgp-substrate: | 0.276 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.009 |
30% Bioavailability (F30%): | 0.113 |
Blood-Brain-Barrier Penetration (BBB): | 0.507 | Plasma Protein Binding (PPB): | 73.03% |
Volume Distribution (VD): | 0.874 | Fu: | 18.17% |
CYP1A2-inhibitor: | 0.353 | CYP1A2-substrate: | 0.925 |
CYP2C19-inhibitor: | 0.42 | CYP2C19-substrate: | 0.553 |
CYP2C9-inhibitor: | 0.842 | CYP2C9-substrate: | 0.78 |
CYP2D6-inhibitor: | 0.112 | CYP2D6-substrate: | 0.384 |
CYP3A4-inhibitor: | 0.901 | CYP3A4-substrate: | 0.333 |
Clearance (CL): | 4.536 | Half-life (T1/2): | 0.748 |
hERG Blockers: | 0.484 | Human Hepatotoxicity (H-HT): | 0.189 |
Drug-inuced Liver Injury (DILI): | 0.976 | AMES Toxicity: | 0.057 |
Rat Oral Acute Toxicity: | 0.08 | Maximum Recommended Daily Dose: | 0.08 |
Skin Sensitization: | 0.067 | Carcinogencity: | 0.03 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.011 |
Respiratory Toxicity: | 0.022 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005037 | 0.361 | D0E6OC | 0.361 | ||||
ENC005977 | 0.347 | D0J0BU | 0.353 | ||||
ENC003306 | 0.346 | D09DHY | 0.326 | ||||
ENC002043 | 0.346 | D08GJO | 0.314 | ||||
ENC003548 | 0.342 | D0A8FB | 0.311 | ||||
ENC001511 | 0.336 | D02LZB | 0.308 | ||||
ENC003618 | 0.331 | D0J1MI | 0.306 | ||||
ENC002381 | 0.331 | D09HDR | 0.305 | ||||
ENC006015 | 0.331 | D0S5RZ | 0.300 | ||||
ENC001805 | 0.330 | D0NJ3V | 0.297 |